{
  "schemaVersion": "wpf-flagship-release-v1",
  "release": "wpf-flagship-weight-management",
  "version": "1.0.0",
  "releaseDate": "2026-11-11",
  "scope": "Five weight-management studies of semaglutide, tirzepatide and retatrutide already evaluated in the WPF Flagship set. Not a systematic or complete review of these agents.",
  "license": {
    "name": "Creative Commons Attribution 4.0 International",
    "identifier": "CC-BY-4.0",
    "url": "https://creativecommons.org/licenses/by/4.0/"
  },
  "licenseScope": {
    "covered": [
      "The stable result identifiers (resultId) and the WPF citation strings",
      "WPF's classification of each study's design (kind)",
      "WPF-written estimand summaries (estimand), the analysis-plan section pointers, and the study-specific limitations (limitations)",
      "The field corrections and their basis notes, and the release changelog",
      "The selection, arrangement and structure of the dataset, and its CSV, BibTeX and JSON renderings",
      "The release metadata and checksum file"
    ],
    "excluded": [
      "The cited papers and their abstracts, figures and tables (publishers and authors)",
      "ClinicalTrials.gov records, posted results, protocols and statistical analysis plans (linked, not redistributed)",
      "Regulator documents and product labels",
      "Bibliographic identifiers and reported numerical facts as stated by their sources",
      "WPF branding, logos and names",
      "WPF films, transcripts and website copy",
      "WPF repository code"
    ],
    "unclearAndExcluded": [
      "Fields that closely restate source reports: population, comparator, endpoint, followUp, result, uncertainty, discontinuation, funder and trial names. Ownership of this wording is unresolved, so it is outside the licensed scope until the Owner decides otherwise."
    ]
  },
  "suggestedAttribution": "World Peptide Foundation, \"WPF Flagship Weight Management\", version 1.0.0 (2026-11-11), https://www.worldpeptidefoundation.org/releases/wpf-flagship-weight-management/1.0.0/release.json. Licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). Please indicate whether you made changes.",
  "releaseUrl": "https://www.worldpeptidefoundation.org/releases/wpf-flagship-weight-management/1.0.0/release.json",
  "resultsSha256": "4d6c04b6a80bdeb929e3b9a23214e46aa805359dd916be37817f5e751b5c59a6",
  "changelog": [
    {
      "version": "1.0.0",
      "date": "2026-11-11",
      "changes": [
        "First pinned release: 5 results with stable ids, identifiers, registry checks, estimands verified against public analysis plans where available, and design-level limitations.",
        "Applied CC BY 4.0 (Owner-approved) to the WPF-owned dataset; scope listed in LICENSE-NOTICE.txt and release.json.",
        "Corrected retatrutide:2 population and comparator fields (automated source validation; no human adjudication recorded)."
      ]
    }
  ],
  "fieldCorrections": [
    {
      "candidateId": "retatrutide:2",
      "field": "population",
      "previous": "Its dose-response relationships with respect to side effects, safety, and efficacy for the treatment of obesity are not known.",
      "corrected": "338 adults with a BMI of 30 or higher, or 27 to under 30 plus at least one weight-related condition",
      "basis": "PubMed abstract (PMID 37366315) and ClinicalTrials.gov NCT04881760 enrollment (338 actual). The stored value was a background sentence, not a population.",
      "checkedOn": "2026-11-11",
      "validation": "automated_source_validation",
      "humanAdjudication": null
    },
    {
      "candidateId": "retatrutide:2",
      "field": "interventionComparator",
      "previous": "We conducted a phase 2, double-blind, randomized, placebo-controlled trial involving adults who had a body-mass index (BMI, the weight in kilograms divided by the square of the height in meters) of 30 or higher or who had a BMI of 27 to less than 30 plus at least one weight-related condition.",
      "corrected": "Once-weekly subcutaneous retatrutide (1, 4, 8 or 12 mg, with differing starting doses in some arms) vs placebo for 48 weeks",
      "basis": "PubMed abstract (PMID 37366315). The stored value was the trial-design sentence, which names no intervention or comparator doses.",
      "checkedOn": "2026-11-11",
      "validation": "automated_source_validation",
      "humanAdjudication": null
    }
  ],
  "labels": {
    "validation": "automated_source_validation",
    "humanAdjudication": "none recorded"
  },
  "results": [
    {
      "resultId": "surmount-5-weight-72w",
      "candidateId": "semaglutide:1",
      "kind": "direct_head_to_head",
      "trial": "SURMOUNT-5 (phase 3b, open-label)",
      "agents": "Tirzepatide vs semaglutide",
      "pmid": "40353578",
      "doi": "10.1056/NEJMoa2416394",
      "registryId": "NCT05822830",
      "population": "751 adults with obesity, without type 2 diabetes",
      "comparator": "Maximum tolerated dose: tirzepatide 10 or 15 mg vs semaglutide 1.7 or 2.4 mg, once weekly",
      "endpoint": "Percent change in weight from baseline to week 72",
      "followUp": "72 weeks",
      "result": "-20.2% with tirzepatide vs -13.7% with semaglutide (least-squares means; P<0.001)",
      "uncertainty": "95% CI -21.4 to -19.1 (tirzepatide); -14.9 to -12.6 (semaglutide)",
      "discontinuation": "Not stated in the abstract; see the full text.",
      "funder": "Eli Lilly",
      "registryResultsPosted": true,
      "registryMasking": "None (open-label)",
      "estimand": "Modified treatment-regimen estimand (the plan's primary): participants included regardless of treatment discontinuation or other anti-obesity medication, except switching to the other study drug. The displayed -20.2% and -13.7% match the registry's ANCOVA result over the full analysis set, which is the method the plan specifies for this estimand (§4.3.1); the publication abstract does not name the estimand, so this is verified by method, not by an explicit label.",
      "analysisPlan": {
        "title": "SURMOUNT-5 Statistical Analysis Plan v3 (approved 23 Oct 2024), ClinicalTrials.gov NCT05822830",
        "url": "https://cdn.clinicaltrials.gov/large-docs/30/NCT05822830/SAP_001.pdf",
        "sections": "§1.1 Primary estimand; §4.3.1 primary analysis; §4.3.2 efficacy-estimand analysis"
      },
      "limitations": [
        "Open-label: participants and investigators knew the assigned drug (registry masking: none).",
        "Compared maximum tolerated doses; the results apply to adults with obesity without type 2 diabetes.",
        "Funded by the manufacturer of tirzepatide."
      ],
      "citation": "SURMOUNT-5 (phase 3b, open-label). Tirzepatide vs semaglutide. PMID 40353578; DOI 10.1056/NEJMoa2416394; NCT05822830. World Peptide Foundation, Flagship weight-management comparison, result surmount-5-weight-72w. https://www.worldpeptidefoundation.org/research/flagship/compare/weight-management#surmount-5-weight-72w",
      "analysisPlanUrl": "https://cdn.clinicaltrials.gov/large-docs/30/NCT05822830/SAP_001.pdf",
      "analysisPlanSections": "§1.1 Primary estimand; §4.3.1 primary analysis; §4.3.2 efficacy-estimand analysis",
      "registryCheckedOn": "2026-11-11",
      "detailUrl": "https://www.worldpeptidefoundation.org/research/flagship/compare/weight-management#surmount-5-weight-72w"
    },
    {
      "resultId": "step-1-weight-68w",
      "candidateId": "semaglutide:4",
      "kind": "separate_placebo_controlled",
      "trial": "STEP 1 (double-blind)",
      "agents": "Semaglutide 2.4 mg vs placebo, plus lifestyle intervention",
      "pmid": "33567185",
      "doi": "10.1056/NEJMoa2032183",
      "registryId": "NCT03548935",
      "population": "1,961 adults with BMI 30 or more (27 or more with a weight-related condition), without diabetes",
      "comparator": "Placebo plus lifestyle intervention (2:1 randomization)",
      "endpoint": "Percent change in body weight and weight reduction of at least 5% (coprimary)",
      "followUp": "68 weeks",
      "result": "-14.9% with semaglutide vs -2.4% with placebo; estimated difference -12.4 percentage points",
      "uncertainty": "Difference 95% CI -13.4 to -11.5",
      "discontinuation": "Primary estimand assessed effects regardless of treatment discontinuation or rescue interventions.",
      "funder": "Novo Nordisk",
      "registryResultsPosted": true,
      "registryMasking": "Quadruple",
      "estimand": "Primary estimand assessed effects regardless of treatment discontinuation or rescue interventions (stated in the publication abstract). The public analysis plan has not been reviewed here.",
      "analysisPlan": null,
      "limitations": [
        "Both arms also received a lifestyle intervention, so the effect is of semaglutide added to lifestyle support.",
        "Enrolled adults without diabetes; not evidence for people with type 2 diabetes.",
        "Funded by the manufacturer of semaglutide."
      ],
      "citation": "STEP 1 (double-blind). Semaglutide 2.4 mg vs placebo, plus lifestyle intervention. PMID 33567185; DOI 10.1056/NEJMoa2032183; NCT03548935. World Peptide Foundation, Flagship weight-management comparison, result step-1-weight-68w. https://www.worldpeptidefoundation.org/research/flagship/compare/weight-management#step-1-weight-68w",
      "analysisPlanUrl": null,
      "analysisPlanSections": null,
      "registryCheckedOn": "2026-11-11",
      "detailUrl": "https://www.worldpeptidefoundation.org/research/flagship/compare/weight-management#step-1-weight-68w"
    },
    {
      "resultId": "surmount-1-weight-72w",
      "candidateId": "tirzepatide:4",
      "kind": "separate_placebo_controlled",
      "trial": "SURMOUNT-1 (phase 3, double-blind)",
      "agents": "Tirzepatide 5, 10 or 15 mg vs placebo",
      "pmid": "35658024",
      "doi": "10.1056/NEJMoa2206038",
      "registryId": "NCT04184622",
      "population": "2,539 adults with BMI 30 or more, or 27 or more with a weight-related complication, excluding diabetes",
      "comparator": "Placebo (1:1:1:1 randomization), including a 20-week dose-escalation period",
      "endpoint": "Percent change in weight and weight reduction of 5% or more (coprimary)",
      "followUp": "72 weeks",
      "result": "-15.0%, -19.5% and -20.9% with 5, 10 and 15 mg vs -3.1% with placebo",
      "uncertainty": "95% CI -15.9 to -14.2, -20.4 to -18.5, -21.8 to -19.9; placebo -4.3 to -1.9",
      "discontinuation": "Treatment-regimen estimand assessed effects regardless of treatment discontinuation, intention-to-treat population.",
      "funder": "Eli Lilly",
      "registryResultsPosted": true,
      "registryMasking": "Double",
      "estimand": "Treatment-regimen estimand, regardless of treatment discontinuation, intention-to-treat population (stated in the publication abstract). The public analysis plan has not been reviewed here.",
      "analysisPlan": null,
      "limitations": [
        "Enrolled adults without diabetes; not evidence for people with type 2 diabetes.",
        "The 72-week period included a 20-week dose escalation, so full-dose exposure was shorter than 72 weeks.",
        "Funded by the manufacturer of tirzepatide."
      ],
      "citation": "SURMOUNT-1 (phase 3, double-blind). Tirzepatide 5, 10 or 15 mg vs placebo. PMID 35658024; DOI 10.1056/NEJMoa2206038; NCT04184622. World Peptide Foundation, Flagship weight-management comparison, result surmount-1-weight-72w. https://www.worldpeptidefoundation.org/research/flagship/compare/weight-management#surmount-1-weight-72w",
      "analysisPlanUrl": null,
      "analysisPlanSections": null,
      "registryCheckedOn": "2026-11-11",
      "detailUrl": "https://www.worldpeptidefoundation.org/research/flagship/compare/weight-management#surmount-1-weight-72w"
    },
    {
      "resultId": "retatrutide-phase2-weight-48w",
      "candidateId": "retatrutide:2",
      "kind": "separate_placebo_controlled",
      "trial": "Retatrutide phase 2 (double-blind)",
      "agents": "Retatrutide 1, 4, 8 or 12 mg vs placebo",
      "pmid": "37366315",
      "doi": "10.1056/NEJMoa2301972",
      "registryId": "NCT04881760",
      "population": "338 adults with BMI 30 or more, or 27 to under 30 plus at least one weight-related condition",
      "comparator": "Placebo (multiple dose arms, 2:1:1:1:1:2:2 randomization)",
      "endpoint": "Primary: percent change in body weight at 24 weeks. Secondary: at 48 weeks",
      "followUp": "48 weeks (primary endpoint at 24 weeks)",
      "result": "At 48 weeks: -8.7% (1 mg), -17.1% (4 mg), -22.8% (8 mg), -24.2% (12 mg) vs -2.1% placebo",
      "uncertainty": "Not reported in the abstract; see the full text.",
      "discontinuation": "Not stated in the abstract; see the full text.",
      "funder": "Eli Lilly",
      "registryResultsPosted": true,
      "registryMasking": "Double",
      "estimand": "Efficacy estimand: the plan's primary estimand, also applied to the 48-week secondary endpoint. Permanent discontinuation of study drug is handled by a hypothetical strategy, asking what the effect would be had participants adhered to treatment. The registry's 24- and 48-week results use a mixed-effects model that excludes data after discontinuation, consistent with this; the displayed 48-week values match the registry's secondary measure.",
      "analysisPlan": {
        "title": "Retatrutide phase 2 Statistical Analysis Plan V4.0 (approved 15 Dec 2022), ClinicalTrials.gov NCT04881760",
        "url": "https://cdn.clinicaltrials.gov/large-docs/60/NCT04881760/SAP_001.pdf",
        "sections": "§1.1 Primary estimand and estimands for secondary objectives; §4.3.2 main analytical approach"
      },
      "limitations": [
        "Phase 2 dose-finding trial of 338 adults split across seven arms, so each arm is small.",
        "The primary endpoint was at 24 weeks; the 48-week results are secondary.",
        "Funded by the manufacturer of retatrutide. A phase 3 outcome is not represented here."
      ],
      "citation": "Retatrutide phase 2 (double-blind). Retatrutide 1, 4, 8 or 12 mg vs placebo. PMID 37366315; DOI 10.1056/NEJMoa2301972; NCT04881760. World Peptide Foundation, Flagship weight-management comparison, result retatrutide-phase2-weight-48w. https://www.worldpeptidefoundation.org/research/flagship/compare/weight-management#retatrutide-phase2-weight-48w",
      "analysisPlanUrl": "https://cdn.clinicaltrials.gov/large-docs/60/NCT04881760/SAP_001.pdf",
      "analysisPlanSections": "§1.1 Primary estimand and estimands for secondary objectives; §4.3.2 main analytical approach",
      "registryCheckedOn": "2026-11-11",
      "detailUrl": "https://www.worldpeptidefoundation.org/research/flagship/compare/weight-management#retatrutide-phase2-weight-48w"
    },
    {
      "resultId": "jama-intern-med-2024-realworld",
      "candidateId": "tirzepatide:6",
      "kind": "observational_cohort",
      "trial": "Rodriguez and colleagues, JAMA Internal Medicine 2024: cohort study, not a randomized trial",
      "agents": "Tirzepatide vs semaglutide (formulations labeled for type 2 diabetes, on or off label)",
      "pmid": "38976257",
      "doi": "10.1001/jamainternmed.2024.2525",
      "registryId": null,
      "population": "41,222 US adults with overweight or obesity on semaglutide (32,029) or tirzepatide (9,193); 18,386 after propensity-score matching; 52.0% of the matched group had type 2 diabetes",
      "comparator": "Semaglutide vs tirzepatide, as prescribed",
      "endpoint": "On-treatment weight change at 3, 6 and 12 months",
      "followUp": "Up to 12 months, on-treatment",
      "result": "Tirzepatide users were more likely to reach 5%, 10% and 15% weight loss (hazard ratios 1.76, 2.54, 3.24)",
      "uncertainty": "Hazard-ratio 95% CIs 1.68-1.84, 2.37-2.73, 2.91-3.61. Weight differences favoring tirzepatide: -2.4% (95% CI -2.5 to -2.2) at 3 months, -4.3% (-4.7 to -4.0) at 6 months, -6.9% (-7.9 to -5.8) at 12 months",
      "discontinuation": "On-treatment analysis: follow-up ended at discontinuation for 55.9% (tirzepatide) and 52.5% (semaglutide), so results describe people while taking the drug and are not comparable to the intention-to-treat results above.",
      "funder": "See the source",
      "registryResultsPosted": null,
      "registryMasking": null,
      "estimand": "Not applicable: observational cohort with no randomized estimand. Follow-up ended at discontinuation for 55.9% of the tirzepatide and 52.5% of the semaglutide group.",
      "analysisPlan": null,
      "limitations": [
        "Observational and not randomized: matched groups can still differ in ways that were not measured.",
        "On-treatment analysis, so results describe people while they were taking the drug.",
        "Formulations labeled for type 2 diabetes were used on or off label, and 52.0% of the matched group had type 2 diabetes."
      ],
      "citation": "Rodriguez and colleagues, JAMA Internal Medicine 2024: cohort study, not a randomized trial. Tirzepatide vs semaglutide (formulations labeled for type 2 diabetes, on or off label). PMID 38976257; DOI 10.1001/jamainternmed.2024.2525. World Peptide Foundation, Flagship weight-management comparison, result jama-intern-med-2024-realworld. https://www.worldpeptidefoundation.org/research/flagship/compare/weight-management#jama-intern-med-2024-realworld",
      "analysisPlanUrl": null,
      "analysisPlanSections": null,
      "registryCheckedOn": null,
      "detailUrl": "https://www.worldpeptidefoundation.org/research/flagship/compare/weight-management#jama-intern-med-2024-realworld"
    }
  ]
}
